5.2
Reações Oxidativas de Fase I: Visão geral
A biotransformação de Fase I, ou funcionalização, é um processo químico crucial que converte medicamentos e outros xenobióticos em formas mais solúvei…
A biotransformação ou funcionalização da Fase I envolve a transformação química de drogas em metabólitos por meio de reações oxidativas, redutoras e/ou hidrolíticas.
Essas reações introduzem ou expõem grupos funcionais polares, aumentando a hidrofilicidade da droga. Seu objetivo principal é a desintoxicação de drogas e facilitar sua excreção do corpo.
As reações oxidativas na fase I envolvem a oxidação de vários sistemas de carbono, incluindo sistemas aromáticos, olefínicos, benzílicos, alílicos, alifáticos, alicíclicos e carbono-heteroátomos.
As enzimas microssomais que catalisam essas reações utilizam oxigênio molecular e NADPH. um agente redutor. Portanto, essas enzimas são chamadas de oxidases de função mista.
Exemplos de medicamentos submetidos a reações oxidativas de fase I incluem fenitoína, diazepam e codeína.
Os metabólitos de fase I resultantes podem exibir atividade farmacológica diminuída, igual ou aumentada e servir como substratos para reações de fase II.
View the full transcript and gain access to JoVE Core videos
Q1: What is the main purpose of phase I oxidative reactions in drug metabolism?
Phase I oxidative reactions transform drugs into metabolites by introducing or exposing polar functional groups, enhancing hydrophilicity. This process facilitates drug detoxification and excretion from the body. These reactions are catalyzed by mixed-function oxidases, which require molecular oxygen and NADPH to oxidize various carbon systems in drug molecules.
Q2: How do mixed-function oxidases catalyze phase I oxidative reactions?
Mixed-function oxidases are microsomal enzymes that catalyze phase I oxidative reactions using molecular oxygen and NADPH, a reducing agent. These enzymes oxidize various carbon systems including aromatic, olefinic, benzylic, allylic, aliphatic, alicyclic, and carbon-heteroatom systems. The oxidation introduces hydroxyl, carbonyl, or other polar functional groups that increase drug water solubility.
Q3: What types of carbon systems can undergo phase I oxidative reactions?
Phase I oxidative reactions can occur at aromatic, olefinic, benzylic, allylic, aliphatic, alicyclic, and carbon-heteroatom systems. For example, aromatic oxidation converts phenytoin to p-hydroxy phenytoin, while aliphatic oxidation transforms ethanol into alcohols or carboxylic acids. Nitrogen-containing compounds like codeine undergo N-demethylation, and sulfur compounds like omeprazole convert to sulfoxides or sulfones.
Q4: What are examples of drugs that undergo phase I oxidative reactions?
Common drugs undergoing phase I oxidative reactions include phenytoin, diazepam, and codeine. Phenytoin is oxidized to p-hydroxy phenytoin, while codeine undergoes N-demethylation to form morphine. These transformations demonstrate how phase I reactions modify drug structures to enhance water solubility and facilitate elimination from the body.
Q5: How do phase I metabolites differ in their pharmacological activity?
Phase I metabolites can exhibit decreased, equal, or increased pharmacological activity compared to the parent drug. These metabolites serve as substrates for phase II conjugation reactions, which further enhance water solubility and promote excretion. The variable activity of phase I metabolites underscores the importance of understanding drug biotransformation pathways in predicting drug effects.
Q6: Why is increasing drug hydrophilicity important in phase I biotransformation?
Increasing hydrophilicity is essential because lipophilic drugs are poorly excreted by the kidneys. Phase I oxidative reactions introduce polar functional groups that enhance water solubility, enabling efficient renal elimination. This transformation is critical for preventing drug accumulation in the body and reducing potential toxicity from prolonged drug exposure.
Q7: What cofactors are required for phase I oxidative reactions to occur?
Phase I oxidative reactions require molecular oxygen and NADPH, a reducing agent, to proceed. Mixed-function oxidases utilize these cofactors to catalyze the oxidation of drug molecules. The availability of these cofactors, particularly NADPH, can influence the rate and extent of phase I drug metabolism in hepatic microsomes.